Overview
AI-driven oncology drug development.
Details
Lantern’s RADR platform identifies patient subsets and biomarkers for in-licensed oncology assets.
Tags
drug-discovery, oncology, biomarkers, public-company
Lantern Pharma
AI-driven oncology drug development. Lantern's RADR platform identifies patient subsets and biomarkers for in-licensed oncology assets.
Visit Website
Drug Discovery & Pharma
drug-discovery oncology biomarkers public-company